Gaster 10%

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Gaster 10%

Property Description
Active Ingredient Famotidine
Form Oral Solution or Suspension
Pharmacological Class Histamine H₂-receptor antagonist (H₂-blocker)
General Purpose Gastric Acid Reduction
Origin Synthetic

Gaster 10%: Chemical Identity and Pharmacological Class

Gaster 10% is a synthetic pharmaceutical preparation whose single active ingredient is the chemical compound Famotidine. Famotidine belongs to the class of Histamine H₂-receptor antagonists (H₂-blockers), which distinguishes it from other acid-reducing agents like proton pump inhibitors. This classification establishes Gaster 10% as an antisecretory agent that functions by interfering with signals that stimulate acid production in the stomach. Gaster 10% is often utilized in settings where precise, liquid administration of Famotidine is necessary, differentiating it from standardized tablet forms.

Understanding the 10% Designation and Formulation

The designation Gaster 10% indicates a specific concentration of Famotidine, typically prepared as a liquid oral solution or suspension in an aqueous vehicle. This specific liquid formulation is a key feature, making it suitable for patients who may have difficulty swallowing solid medication or who require the flexibility of a liquid dosage form. The 10% figure defines the potency of this specific preparation, which is designed for either oral or, in clinical contexts, intravenous parenteral administration.

What is the General Purpose of an H₂-Blocker?

The general purpose of this medicine is rooted in its potent antisecretory action, which is to significantly inhibit the production of gastric acid. The drug achieves this by selectively blocking the H₂ receptors found in the stomach lining. By interrupting this signaling pathway, Famotidine reduces the volume and corrosive nature of digestive fluids. This mechanism provides the core therapeutic benefit of mitigating discomfort associated with excess stomach acidity, frequently experienced as heartburn and acid indigestion.

Regulatory References

  1. Famotidine - StatPearls
  2. Famotidine: MedlinePlus Drug Information

What side effects are possible with Gaster 10%?

Possible Side Effects and Safety Information

The safety profile of Famotidine, the active component in Gaster 10%, is defined by regulatory classification of adverse reactions, which are grouped by frequency and the body systems affected. These official classifications establish the spectrum of potential risks, from common, non-serious events to rare, clinically important reactions.


Frequency-Classified Adverse Reactions

Adverse reactions are formally categorized based on official incidence rates documented in regulatory labeling. The most Common reactions reported include Headache, Dizziness, Constipation, and Diarrhoea. Effects classified as Uncommon involve symptoms such as Nausea/Vomiting, Abdominal discomfort, Flatulence, and Rash.


System-Organ-Class (SOC) Safety Groups and Serious Reactions

Regulatory documents group less frequent, but significant, adverse effects across multiple systems, including Psychiatric disorders (e.g., confusion, disorientation) and Hepato-biliary disorders (e.g., liver enzyme abnormalities). The official safety profile also includes the possibility of rare, Serious Adverse Reactions, such as Anaphylaxis, severe cutaneous events like Stevens Johnson Syndrome, and certain Cardiac arrhythmias (e.g., QT prolongation), particularly when administered intravenously.


Population-Specific Safety Considerations

The prescribing information notes specific safety considerations for certain patient populations. Elderly patients and individuals with renal impairment are documented as having an increased susceptibility to Central Nervous System (CNS) adverse reactions, such as confusion and hallucinations, due to changes in drug clearance. Furthermore, the active ingredient is excreted in breast milk, requiring specific caution according to regulatory guidance.

Overdose and Emergency Response

The regulatory profile for Gaster 10% (Famotidine) overdose focuses on documented clinical manifestations and mandatory emergency actions. Overdosage symptoms are officially stated to be similar to the adverse reactions experienced during use at recommended dosages.

At high exposures, severe effects primarily involve the Central Nervous System (CNS), which may include confusion, delirium, hallucinations, agitation, and seizures. Cardiovascular complications, such as atrioventricular (AV) block, have also been reported with this class of medication.

A critical consideration in overdosage is the patient's underlying health status. Regulatory documents note that elderly patients and individuals with moderate or severe renal impairment face an increased risk of severe CNS events due to reduced drug clearance.

Emergency actions must be sought immediately. If a suspected overdose results in severe signs like collapse, trouble breathing, or a seizure, emergency services must be contacted right away. For all other exposures, patients should immediately contact a Poison Control Center. Management relies on symptomatic and supportive treatment, including monitoring and removal of any unabsorbed material from the gastrointestinal tract. No specific antidote is known for famotidine overdosage.

Therapeutic Uses of Gaster 10%

What Gaster 10% Treats: Main Uses and Benefits

Gaster 10% is used to help manage various symptoms arising from functional digestive discomfort. The primary benefit for the patient is temporary symptom relief from common upper gastrointestinal issues. This medication is commonly utilized in clinical scenarios involving stomachache, stomach upset, heartburn, and retching.

The active component in Gaster 10% may assist in managing conditions linked to stomach acid. The medicine is intended to offer temporary relief for common, acute episodes of indigestion. The goal of using Gaster 10% is to support the patient’s comfort and well-being during symptom episodes.


Quick Fact: Relief for Heartburn and Stomach Upset

Eligibility and Restrictions for Use

Who Can and Cannot Use Gaster 10% (Famotidine) — Official Regulatory Information

The eligibility profile for Gaster 10% is defined by absolute contraindications, age-related limits, and condition-based restrictions, based on regulatory labeling.

Classification Rule/Restriction
Contraindicated History of serious hypersensitivity or allergic reaction to famotidine or other H2 receptor antagonists.
Conditional Use Patients with moderate to severe renal impairment ( CrCl < 60 mL/min) must receive dosage adjustment or extended dosing intervals due to delayed excretion and risk of CNS adverse effects.
Age-Related Limits Children (under 12-16 years, depending on formulation and country) are generally excluded from Over-the-Counter (OTC) use; Geriatric patients may require lower doses and monitored renal function due to increased risk of CNS effects.
Specific Exclusions Pregnancy and Lactation generally require caution or discontinuation of the drug, as the drug is known to be excreted in breast milk. Gastric malignancy must be ruled out before initiating therapy, as symptom relief does not exclude its presence.

Use is generally considered appropriate for adults within the approved age range who do not have hypersensitivity and have normal or appropriately adjusted renal function. Patients with severe renal impairment are at a higher risk for adverse reactions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Famotidine, the active ingredient in Gaster 10%, has officially documented interaction patterns primarily centered on two pharmacokinetic effects: a reduction in gastric acidity and interference with drug clearance pathways.

Pharmacokinetic Interactions

Famotidine's acid-reducing effect can significantly reduce the systemic exposure of other oral medicines that require an acidic pH for dissolution and absorption. Regulatory labeling includes substances such as the tyrosine kinase inhibitors Erlotinib, Dasatinib, and Acalabrutinib, and the antifungals Ketoconazole and Itraconazole in this category. For co-administration with Erlotinib, the regulatory requirement is to administer Erlotinib two hours before or ten hours after the Famotidine dose.

Separately, official documents caution that Famotidine may cause substantial increases in the plasma concentrations of Tizanidine, a CYP1A2 substrate. Co-administration is formally advised to be avoided where possible. Famotidine also affects the clearance of Erdafitinib by inhibiting the OCT2 renal transporter.

Interaction Considerations

Context Restriction or Caution
Tizanidine Advised to be avoided due to risk of increased exposure.
Renal Impairment Increased Famotidine exposure heightens the risk of interaction-related CNS effects.
Alcohol Co-consumption may increase the likelihood of effects such as dizziness and headache.

Co-administration is contraindicated in patients with a history of serious hypersensitivity to Famotidine or any other H₂-receptor antagonist.

Mechanism of Action

How Gaster 10% Works: Mechanism of Action

Targeting the Histamine H2 Receptor

Gaster 10% works by having its active ingredient, Famotidine, function as a competitive antagonist at the Histamine H2 receptors located on the gastric parietal cells. This interaction precisely blocks the primary molecular signal (histamine) responsible for stimulating the production of stomach acid.

⬇️ Interrupting the Acid Secretion Cascade

The receptor blockade halts the intracellular G s protein and adenylate cyclase cascade, leading to a critical reduction in the internal cell signal required for acid generation. This mechanistic sequence prevents the full activation of the final acid-secreting engine, the H^+/ K^+-ATPase (Proton Pump).

⬆️ Resulting Modulation of Gastric pH

The functional inhibition of the proton pump leads to a marked reduction in hydrogen ion ( H^+) secretion into the stomach lumen. This mechanism directly results in the elevation of intragastric pH, thereby chemically mitigating the acidity of the stomach’s digestive fluids.

️ Mechanistic Limitations (Tachyphylaxis)

The mechanism is prone to tachyphylaxis, a rapid physiological tolerance that limits the duration or magnitude of its acid-suppressing mechanism, particularly regarding the nocturnal acid suppression activity. This decline is partly due to the mechanism's limited capacity to block acid secretion signals from non-histamine mediators like gastrin and acetylcholine.

Dosage and Administration Information

How to use Gaster 10%: Administration Guidelines

This section outlines the administration of Famotidine (the active component of Gaster 10%), focusing strictly on how the medicine is used.


Approved Administration Routes and Schedules

Famotidine is used via two main routes of administration: Oral (which includes the solution/suspension form) and Intravenous (IV). The IV route is reserved for hospitalized patients who cannot tolerate oral medication.

Usage Pattern Standard Adult Dosing (Normal Renal Function) Frequency Duration Pattern
Active Ulcer Treatment 40 mg OR 20 mg Once daily (at bedtime) OR Twice daily Up to 8 weeks
Pathological Hypersecretory Conditions Initial: 20 mg; Max: 160 mg Every 6 hours As clinically indicated
Risk Reduction of Ulcer Recurrence 20 mg Once daily (at bedtime) Up to 1 year

Preparation and Administration Context

  • Intake Timing: Famotidine may be taken with or without food. For the liquid formulation, the container should be shaken vigorously for 5 to 10 seconds before each use to ensure proper mixing, and the dose must be measured accurately with a suitable device.
  • IV Administration: Intravenous administration requires the drug to be given slowly as an injection over at least 2 minutes or as an infusion over 15 to 30 minutes.

Population-Specific Use Adjustments

Dosage modifications are utilized for adult patients with impaired renal function. For individuals with moderate to severe renal impairment (creatinine clearance <60 mL/min), the dosage is typically reduced by 50% or the dosing interval extended to between 36 and 48 hours to prevent accumulation.

Recent Clinical Evidence

Research evidence / Overview of studies for Gaster 10%

The following is an overview of the research and studies conducted on the active component of Gaster 10% (Famotidine). This summary describes the structure of the evidence and what the studies examined, but it does not provide clinical advice or discuss safety information.


Evidence for Established Gastrointestinal Conditions

The active ingredient in Gaster 10% was studied for use in conditions such as ulcers in the stomach and small intestine, as well as erosive acid reflux disease (GERD). The foundational research included Randomized Controlled Trials (RCTs) and supporting Systematic Reviews that provided data related to the regulatory acceptance of this medicine. Researchers examined physical outcomes, such as confirmed ulcer healing and the healing of the lining (mucosal healing) in erosive conditions. They also monitored the rate of recurrence. Study populations typically included adults and older adults with established, confirmed diagnoses.

Studies reported measurements related to changes in tissue damage and the rate of maintaining a healed state across observation periods. Findings contribute to the evidence base supporting the use of this pharmacological class. However, the core evidence base relies significantly on historical studies. The available evidence primarily focuses on historical studies and early randomized controlled trials. Long-term outcomes and the rate of recurrence prevention beyond one year are not as extensively characterized in certain patient subgroups.


Evidence for Symptom Relief and Dyspepsia

Research also explored the active component in trials assessing short-term or episodic symptom patterns, such as heartburn and general acid indigestion (dyspepsia). Studies conducted during periods of increased symptom activity included Short-term Randomized Controlled Trials and supporting Systematic Reviews. Researchers monitored patient-reported outcomes describing perceived discomfort, focusing on time intervals related to symptom changes and any changes in the intensity of discomfort.

Studies reported how symptoms evolved in the observed populations, particularly noting patterns related to the speed of symptom change in the immediate aftermath of administration. Research highlights changes measured during the study period, showing patterns related to symptom reporting compared to other treatments or placebo. However, follow-up durations were limited for studies examining acute relief, with very short observation periods. Findings were mixed in highly specific subgroups, indicating that evidence quality varies across studies, and results apply only to the specific populations that were included in the studies.

Key Studies & References

  1. Famotidine: Indications, Mechanism of Action, Administration, and Pharmacokinetics (StatPearls Review)
  2. Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer

Frequently Asked Questions (FAQ)

Common questions about Gaster 10% (FAQ)


Q: Is Gaster 10% safe to use during pregnancy, based on official information?

Regulatory documents state that Famotidine, the active ingredient, should be used during pregnancy only if it is clearly needed. A determination must be made to assess whether the potential benefits are considered to outweigh any potential risks to the developing fetus. Official information reports that animal studies have not shown evidence of harm.


Q: What information is available about Gaster 10% and breastfeeding?

Official information indicates that the active component, Famotidine, is detectable in human milk. Regulatory guidance suggests that a decision must be made to either discontinue nursing or stop using the drug. This decision is to be made after considering the importance of the medicine for the mother’s health.


Q: Does Gaster 10% have any known interaction with alcohol?

Some drug interaction guidelines list a minor caution regarding the co-consumption of Famotidine and alcohol. According to official documents, using the two together may increase the likelihood of certain effects, such as dizziness and headache.


Q: Can I take Gaster 10% if I'm taking vitamins or supplements?

Official drug labels do not generally list direct interactions with common vitamins. However, because Famotidine is an acid-reducing agent, its presence can reduce the absorption of other oral medicines that require an acidic stomach environment to be processed by the body. This general principle is important to consider.


Q: Is it common for people to get headaches when starting Gaster 10%?

Headache is classified as a common adverse reaction in official regulatory documents describing side effects. While the information confirms the frequency of this effect, available documents do not generally specify if the symptom is more pronounced during the initial period of taking the medication.


Q: Is it normal to feel a bit dizzy after starting Gaster 10%?

Dizziness is classified as a common adverse reaction in official regulatory documents. As with headache, while official information confirms its commonality, there is no specific data highlighting whether this symptom is particularly more frequent during the initial period of taking the medication.


Q: Is it okay to drive while taking Gaster 10%?

Regulatory warnings indicate that the medication can affect a person’s ability to drive or operate machinery. Regulatory caution advises against driving until a person knows how the medicine affects them, due to the risk of sleepiness or dizziness.


Q: Does Gaster 10% affect mood or mental clarity?

The official safety profile includes possible adverse reactions affecting Psychiatric disorders and the Central Nervous System. These effects can include symptoms such as confusion, disorientation, or anxiety. Regulatory documents note these effects are more common in elderly patients or those with reduced kidney function.


Q: Is Gaster 10% intended for long-term or short-term use?

Famotidine is authorized for both short-term and longer-term uses, depending on the condition being addressed. For instance, official schedules list short-term use for treating active ulcers, but long-term use (up to one year) is sometimes prescribed for the reduction of ulcer recurrence.


Q: Is Gaster 10% the same kind of drug as Gaster 5%?

Both Gaster 10% and Gaster 5% contain the same active ingredient, Famotidine. The 10% and 5% figures refer to the specific concentration or strength of the preparation, which may be different formulations designed for different uses or dosing needs.


Q: Why do people say Gaster 10% makes them feel sleepy?

While direct 'sleepiness' (somnolence) may not always be explicitly listed as a common effect, the official safety profile includes Dizziness and general Central Nervous System (CNS) adverse effects. Regulatory warnings also caution that the drug may cause a person to feel sleepy and affect activities requiring focus.


Q: If I miss a day of Gaster 10%, will that affect how it works?

Patient information generally describes an approach to a missed dose: taking it when remembered, unless it is close to the next scheduled dose. In situations where it is close to the next dose time, the instruction is to skip the missed dose. Taking extra or double doses is not advised.


Q: Do you need to stop Gaster 10% gradually, or can you stop suddenly?

There is no specific official tapering schedule defined for Famotidine discontinuation in general regulatory information. However, regulatory discussions regarding this class of acid-reducing drugs have noted that stopping use after an extended period may result in a temporary increase in stomach acid production (rebound effect).


Q: What happens if I accidentally take Gaster 10% twice in one day?

Overdose symptoms associated with this class of medicine can include agitation, confusion, or an irregular heartbeat. When a person believes they have taken more than the intended amount, seeking immediate medical attention is the recommended course of action.


Q: Is there a generic version of Gaster 10% available?

The active ingredient in Gaster 10%, Famotidine, has been approved by regulatory bodies and is available in various generic versions manufactured by different companies.


Q: Are there any food or drinks that interact with Gaster 10%?

Famotidine can be taken with or without food as per regulatory labels, and most specific food and drink interactions are not highlighted in major warnings. A minor caution exists regarding alcohol, as it may increase the risk of certain side effects.


Q: Can teenagers or children use Gaster 10%?

The official labeling for Famotidine does authorize use in certain pediatric populations. Over-the-counter (OTC) use is typically for children aged 12 and older, while use in younger children for specific conditions generally requires a prescription and monitoring.


Q: Is Gaster 10% habit-forming or addictive?

Famotidine is not classified as a Controlled Substance by major regulatory bodies. However, official information notes that after long-term use of acid-reducing medications, patients may experience a rebound acid hypersecretion (temporary increase in acid) upon stopping the drug.


Q: How long does Gaster 10% stay in your system?

The drug is primarily eliminated from the body unchanged through the urine. In individuals with normal kidney function, the drug's elimination half-life is characterized as approximately 2 to 4 hours.


Q: Can I take Gaster 10% with common supplements like Omega-3 or Vitamin D?

Official drug interaction databases generally show no known interactions between Famotidine and common supplements like Omega-3 or Vitamin D. Patients are informed that the acid-reducing effect may still reduce the absorption of other oral medicines.


Q: What does the official patient leaflet say about Gaster 10% and caffeine?

Famotidine is not typically considered to have a significant interaction with caffeine. However, consuming caffeine is known to stimulate the production of stomach acid, which may counteract the intended therapeutic effect of the medication.


Q: Is it better to take Gaster 10% in the morning or at night?

Official regulatory dosing schedules for certain conditions, such as ulcer treatment or recurrence reduction, often include a recommended dose taken once daily at bedtime. For other authorized conditions, the drug may be prescribed for administration twice daily.


Q: What information exists about Gaster 10% and fertility?

Official regulatory documents include data from animal studies that have been performed with the active ingredient. These studies did not reveal significant evidence of impaired fertility or negative effects on reproductive performance. Similar findings were observed in laboratory studies on human sperm.


Q: Can Gaster 10% be used simultaneously with anti-depressants?

Official information warns that Famotidine can increase the risk of an irregular heart rhythm when used with certain types of anti-depressants, specifically tricyclic antidepressants. For patients using both medications, monitoring by a healthcare professional is considered necessary.

How should Gaster 10% be stored and disposed of?

How to Store and Dispose of Gaster 10%

The storage and disposal of Gaster 10% (famotidine oral suspension) must adhere to official regulatory requirements to maintain product integrity and safety.

Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F).
Protection Protect from freezing, light, and excessive heat. Keep the container tightly closed.
Stability Any unused portion of the suspension must be discarded after 30 days from the date of initial preparation.
Safety The medicine must be kept out of the sight and reach of children.

Disposal Instructions

Official guidelines recommend disposal through drug take-back programs when they are available. The product must not be flushed down a toilet or poured down a drain unless regulatory instructions explicitly state otherwise. If take-back options are not available, the medicine should be mixed with an undesirable substance (e.g., coffee grounds) in a sealed container before being placed in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Gaster 10% found in:

A-Z Index: